Volume 83, Issue 2, Pages 264-271 (February 2013) Low mannose-binding lectin serum levels are associated with reduced kidney graft survival  Jakob T. Bay, Søren S. Sørensen, Jesper M. Hansen, Hans O. Madsen, Peter Garred  Kidney International  Volume 83, Issue 2, Pages 264-271 (February 2013) DOI: 10.1038/ki.2012.373 Copyright © 2013 International Society of Nephrology Terms and Conditions

Figure 1 Serum levels of mannose-binding lectin (MBL) in kidney transplant patients according to MBL2 genotypes (P<0.00001). The genotypes YA/YA, YA/XA, XA/XA, and YA/YO corresponding to medium/high levels of functional MBLs are grouped and the genotypes XA/YO and YO/YO corresponding to low levels of functional MBLs are grouped. Kidney International 2013 83, 264-271DOI: (10.1038/ki.2012.373) Copyright © 2013 International Society of Nephrology Terms and Conditions

Figure 2 Five-year death-censored kidney graft survival according to serum mannose-binding lectin (MBL) level. (a) All patients transplanted with either a deceased or a living donor (P=0.0345). (b) Non-human leukocyte antigen (HLA)-immunized patients transplanted with either a deceased or a living donor kidney (P=0.0176). (c) HLA-immunized patients transplanted with either a deceased or a living donor kidney (P=0.4019). (d) All patients transplanted with a deceased donor kidney (P=0.0007). (e) All patients transplanted with a living donor kidney (P=0.0777). (f) Non-HLA-immunized patients transplanted with a deceased donor kidney (P=0.0004). Kidney International 2013 83, 264-271DOI: (10.1038/ki.2012.373) Copyright © 2013 International Society of Nephrology Terms and Conditions

Figure 3 Five-year death-censored kidney graft survival according to MBL2 genotypes. (a) The high-expression MBL2 group was defined as the YA/YA, YA/XA, XA/XA, and YA/YO haplotypes, whereas the low-expression group was defined as the XA/YO and YO/YO haplotypes. All patients transplanted with either a deceased or a living donor (P=0.1684). (b) Non-human leukocyte antigen (HLA)-immunized patients transplanted with either a deceased or a living donor (P=0.0321). (c) HLA-immunized patients transplanted with either a deceased or a living donor kidney (P=0.2429). (d) All patients transplanted with a deceased donor kidney (P=0.0199). (e) All patients transplanted with a living donor kidney (P=0.2549). (f) Non-HLA-immunized patients transplanted with a deceased donor kidney (P=0.0024). Kidney International 2013 83, 264-271DOI: (10.1038/ki.2012.373) Copyright © 2013 International Society of Nephrology Terms and Conditions